Transthyretin amyloid cardiomyopathy
Conditions
Brief summary
Quantification of myocardial microcalcification on 18F-sodiumfluoride PET/CT and quantification of cardiac autonomic function on [123I]MIBG imaging.
Detailed description
Change in myocardial microcalcification activity and myocardial innervation on 18F-sodiumfluoride PET/CT and [123I]-MIBG respectively, Cardiac indices on magnetic resonance imaging, such as left ventricular ejection fraction, left ventricular mass, extracellular volume and global longitudinal strain, Cardiac biomarkers including NT-ProBNP and high-sensitivity cardiac troponin I, Clinical measures, such as 6MWT test, KCCQ-OS and Norfolk QOL‐DN
Interventions
DRUGRadio-Flu 0
DRUG1 - 4 GBq/ml oplossing voor injectie
DRUGMIBG (I123) 74 MBq/mL oplossing voor injectie
Jobenguaan (123I)
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Change in myocardial microcalcification activity and myocardial innervation on 18F-sodiumfluoride PET/CT and [123I]-MIBG respectively, Cardiac indices on magnetic resonance imaging, such as left ventricular ejection fraction, left ventricular mass, extracellular volume and global longitudinal strain, Cardiac biomarkers including NT-ProBNP and high-sensitivity cardiac troponin I, Clinical measures, such as 6MWT test, KCCQ-OS and Norfolk QOL‐DN | — |
Primary
| Measure | Time frame |
|---|---|
| Quantification of myocardial microcalcification on 18F-sodiumfluoride PET/CT and quantification of cardiac autonomic function on [123I]MIBG imaging. | — |
Countries
Netherlands
Outcome results
None listed